Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 04, 2023

SELL
$22.82 - $35.32 $68 - $105
-3 Reduced 3.57%
81 $1,000
Q4 2022

Feb 03, 2023

BUY
$25.35 - $31.96 $2,129 - $2,684
84 New
84 $2,000
Q2 2022

Jul 18, 2022

BUY
$20.62 - $37.15 $1,546 - $2,786
75 Added 187.5%
115 $3,000
Q4 2021

Jan 24, 2022

BUY
$29.21 - $44.64 $1,168 - $1,785
40 New
40 $1,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Ellevest, Inc. Portfolio

Follow Ellevest, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ellevest, Inc. with notifications on news.